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Low-dose intra-arterial contrast-enhanced
MR aortography in patients based
on a theoretically derived injection protocol
Abstract Multiple intra-arterial con-
trast agent injections are necessary
during MR-guided endovascular in-
terventions. In respect to the approved
limits of maximum daily gadolinium
dose, a low-dose injection protocol is
mandatory. The objective of this study
was to derive and apply a low-dose
injection protocol for intra-arterial 3D
contrast-enhanced MR aortography in
patients. Injection rate (Qinj), concen-
tration of injected gadolinium [Gd]inj
and aortal blood flow rate (Qblood)
were included for the theoretical
evaluation of signal intensity (SI) of
the arterial lumen. SI simulations were
carried out at Qinj=2 versus 4 ml/s in
the [Gd]inj range between 0–500 mM.
Qinj and [Gd]inj with SI above the 75%
threshold of the maximal SI were
regarded as optimal injection param-
eters. [Gd]inj=50 mM and Qinj=4 ml/s
were considered as optimal and were
administered in five patients for 3D
MR aortography. All images revealed
clear delineation of the abdominal
aorta and its major branches. Mean±
SD of contrast-to-noise ratios of the
abdominal aorta, common iliac and
renal artery were 70.2±15.2, 58.6±
12.3 and 67.4±12.3. Approximately
seven intra-aortal injections would be
permissible in patients during MR-
guided interventions without exceed-
ing the maximal dose of gadolinium.
Keywords Gadolinium . Intra-arterial .
DSA . MR aortography
Introduction
Atherosclerosis is the leading cause of morbidity and
mortality in the Western world. It is a non-inflammatory
disease of the vessel wall leading to thickening and loss of
the vessel wall’s elasticity. Its clinical presentations include
stroke, coronary heart disease, and peripheral arterial oc-
clusive disease (PAOD), which predominantly arise from
complications of vessel stenoses, occlusions, aneurysms,
or dissections. X-ray digital subtraction angiography (DSA)
is regarded as the standard of reference in the diagno-
sis of arterial lesions. DSA-guidance is also used for
endovascular therapies like percutaneous transluminal an-
gioplasty (PTA) or stent placement. In the past decade,
intravenous contrast-enhanced MR angiography (CE-MRA)
has gained broad acceptance among clinicians and has be-
come a valuable diagnostic tool in the clinical routine [1–7].
The advantages of CE-MRA are well documented and
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include the lack of X-ray exposure of the patient and ex-
aminer, use of minor nephrotoxic contrast agent with low
allergic potential, excellent soft-tissue contrast, and three-
dimensional (3D) arterial visualization.
In the face of the fast-growing MR technology, sever-
al investigators have made efforts to extend the field of
MR angiography towards MR-guided endovascular inter-
ventions [8–18]. One of the primary goals of these efforts
is to obtain high-spatial-resolution intra-arterial 3D CE-
MR angiograms. Adequate arterial enhancement is re-
quired by low-dose intra-arterial contrast agent injection
through the arterial access provided by the interven-
tional procedure. High contrast-to-noise ratios (CNR) of
the vessel lumen are an important precondition for the
localization of stenoses and occlusions. This is manda-
tory to assess precise tracking of endovascular devices
like guide wires and catheters.
Due to the paramagnetic properties of gadolinium (Gd)-
based contrast agents, the blood concentration of gadolin-
ium ([Gd]blood) must meet a target range during MRA data
acquisition. [Gd]blood values below this range will result
in a signal loss because of insufficient T1 shortening,
while [Gd]blood values above this range will cause rapid
spin-dephasing leading to a T2/T2*-dependent reduction
of the MR signal. The optimal concentration of gadolin-
ium in blood depends on several factors including the
blood flow rate (Qblood), injection rate (Qinj), and con-
centration of injected gadolinium ([Gd]inj). A theoretical
model has been introduced to determine the target range
of optimal gadolinium concentration in blood [Gd]blood
[9–17,19]. Based on this model, a low-dose injection
protocol for intra-arterial 3D CE-MRA of the infraingui-
nal arteries has been derived and was successfully val-
idated for the visualization of thigh and calf arteries in
PAOD patients [8].
In contrast to the infrainguinal arteries, endovascular
interventional procedures in the abdominal aorta are less
common. Nevertheless, good luminal signal enhancement
of the abdominal aorta during an interventional procedure
is required for the retrograde tracking and positioning
of guide wires and catheters to sound major branching
arteries, the coeliac trunk, the superior mesenteric, the
inferior mesenteric, and the renal artery. Until now, no
low-dose intra-arterial injection protocol for MR aortog-
raphy in humans has been proposed or investigated in
patients. A theoretical model can be adapted to the flow
conditions of the human aorta. However, the range of
aortal flow rates is rather large compared to the range of
blood flow rates in the lower extremities.
The purpose of this study was to simulate a low-dose
intra-arterial injection protocol for optimal signal enhance-
ment of the human aorta. The derived injection protocol
was applied in patients to assess the value of low-dose
intra-arterial 3D CE-MR aortography for the depiction of
the aorta and its major arterial branches.
Materials and methods
Simulations
For particular T1-weighted imaging sequences and given
acquisition parameters (repetition time: 2.73 ms; echo time:
0.89 ms and acquisition time: 20.3 s), the contrast agent
concentration in blood determines T1 shortening and there-
fore a signal intensity (SI) of the blood. The contrast agent
concentration (relaxivities of R1 and R2) in blood depends
on several parameters such as the arterial Qblood, Qinj, and
[Gd]inj. (equation 3 in the appendix). When complete
mixing of contrast agent with native blood is assumed, an
appropriate low-dose intra-arterial injection protocol can
be derived. In our study we are focused on the flow con-
dition of the human abdominal aorta with flow blood rates
≤30 ml/s. In the appendix the expressions relating the signal
intensity (SI) of a spoiled gradient-echo sequence to the
parameters Qblood, Qinj, and [Gd]inj via [Gd]blood are de-
scribed in detail. Using these equations we theoretically
calculated the SI as a function of the injection parameters,
[Gd]inj and Qinj, regarding aortal flow conditions for the
acquisition parameters applied.
Considering the intraindividual variation of the aortal
blood flow rates in patients, simulations were performed
for Qblood ranging from 0 to 30 ml/s, which was increased
in intervals of 10 ml/s. Further, the effect of two injection
rates, Qinj=2 ml/s and 4 ml/s, of SI was considered. For
these parameters the SI in the aortal lumen as a function
of [Gd]inj from 0 up to 500 mM was simulated. In our
patient study we used commercially available Gd-DTPA
(Magnevist, Schering, Berlin, Germany) as contrast agent
distributed with a full-strength concentration of 500 mM,
containing 78.63 mg gadolinium. This stock solution of
Gd-DTPA was diluted with physiological saline to obtain
a gadolinium concentration of 50 mM. From these sim-
ulations a low-dose intra-arterial injection protocol for
optimal signal enhancement of the aortal lumen in hu-
mans has been derived.
The lowest injected gadolinium concentration provid-
ing a SI above 75% of the SI maximum for all aortal
blood flow rates and its corresponding injection rate were
regarded as optimal. This optimal low-dose injection pro-
tocol was applied in patients for intra-arterial 3D CE-
MR aortography. All simulations were performed within
the Matlab programming environment (Mathworks, MA,
USA).
Patients
The study protocol was approved by our institutional re-
view board. Written informed consent was obtained from
all patients prior to inclusion. Within a period of 6 months,
five patients (four men, one woman, 56–67 years) were
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enrolled in this study. Four of the patients suffered from
symptomatic PAOD and were treated with PTA and/or
stent placement under DSA-guidance immediately before
MR aortography. One patient was a living kidney donor.
After X-ray guided angiography (and angioplasty), intra-
aortal 3D CE-MRA was performed. Exclusion criteria of
this study included all generally accepted contraindications
for MRI, e.g., pacemakers, implantable cardioverter de-
fibrillators, and claustrophobia.
Retrograde percutaneous puncture of the common fem-
oral artery was performed under X-ray fluoroscopy. For
reference purpose, diagnostic X-ray angiograms were car-
ried out in anterior-posterior (a.-p.) projections. To delin-
eate the abdominal aorta and its run-off, 20 ml of non-ionic
contrast agent (Ultravist 300, Schering, Berlin, Germany)
was automatically injected at an injection rate of 18 ml/s
(Angiomat-6000 Liebel-Flarsheim, Tyco Healthcare/Mal-
linckrodt, St. Louis, MO, USA). After conventional an-
giography and/or angioplasty, an MR-compatible 4F or
6F introducer sheath remained in the common femoral
artery. X-ray fluoroscopic guidance was used to place
the tip of an Omniflush-catheter (AngioDynamics, Queens-
bury, NY) in the suprarenal position. A permanent saline
flush ensured the patency of the device during patient
transport from the angio-suite to the MR-scanner.
MR imaging
All MR imaging was performed on a clinical 1.5-T MR-
Scanner (Avanto, Siemens Medical Solutions, Erlangen,
Germany). For signal detection a phased array surface coil
was used. Patients were examined in the supine position
with feet first in the MR scanner. Contrast-enhanced data
sets of the abdominal aorta, its major branches and the
common iliac artery were acquired in the coronal plane
with a 3D fast low angle shot (FLASH) gradient-echo
sequence with fat suppression using the following acqui-
sition parameters: repetition time, 2.73 ms; echo time, 0.89
ms; flip angle, 25°; field-of-view, 420×378 mm2; matrix:
320×220; one slab of 60 partitions interpolated by zero
filling to 80 (slab thickness: 96 mm, slice thickness: 1.6
mm interpolated by zerofilling to 1.2 mm). Seventy-five
percent partial Fourier was applied in both phase-encod-
ing directions to reduce the acquisition time to 20.3 s.
Asymmetric k-space sampling was performed. The center
of the k-space was acquired after 6.6 s.
Commercially available Gd-DTPA (Magnevist, Scher-
ing, Berlin) distributed with a full-strength concentration
of 500 mM was used as contrast agent. The stock solu-
tion of Gd-DTPA was diluted with physiological saline to
obtain a gadolinium concentration of 50 mM. The injec-
tion rate was 4 ml/s for a duration of 15 s. This corre-
sponds to a total dose of 3.0 mmol gadolinium (50 mM×
4 ml/s×15 s). The injection length of 15 s ensures cover-
age of 75% of the k-space including the center of the
k-space during arterial enhancement. The injection was
carried out automatically using a power injector (Spectris,
Medrad Indianola, PA, USA). Intra-aortal gadolinium
injection and MRA data acquisition were started simul-
taneously. Prior to gadolinium administration, a native
image was acquired to allow digital mask subtraction.
Anterior-posterior maximum intensity projections (MIPs)
were reconstructed from the intra-arterial 3D CE-MR
aortographies.
For quantitative assessment, CNR of the infrarenal ab-
dominal aorta, the common iliac, and the renal artery was
determined. The SI of the unsubtracted source images was
measured in the regions of interest (ROI). The size of the
ROI was approximately 1.2 cm2. CNR values of the aor-
tal lumen were calculated according to CNR=(SIblood−
SItissue)/SDair, where SIblood and SItissue refer to the SI of
the vessel lumen and the adjacent musculature, respec-
tively. SDair refers to the standard deviation of SI measured
in a ROI outside the body.
Results
Simulations
Figure 1a shows the results of the simulation of the model
function for Qinj=2 ml/ and Fig. 1b for Qinj=4 ml/s. The
horizontal lines indicate the 75% threshold of maximum SI
used for the determination of optimal injection parameters.
The theoretically predicted SI as a function of [Gd]inj
displays a steep increase until a rather broad maximum is
attained. Following the maximum, a relatively slow de-
crease of the SI is observed. Rather low SI values are found
for the highest [Gd]inj=500 mM. A general finding for
paramagnetic compounds is that the given signal gain is
based on a T1 shortening, but is in competition with the
signal loss due to the T2* effect, which is becoming
superior to the T1 effect. The decline of the SI curve after
peaking has to be attributed to the increase of T2* signal
loss due to spin-dephasing.
Generally, at a fixed injection rate, lower [Gd]inj is
needed for slower blood flow rates in order to reach the
maximum SI and vice versa. On the other hand, for a par-
ticular blood flow rate lower [Gd]inj is required at higher
injection rates and vice versa. For example, for Qinj=2 ml/s
and Qblood=10 ml/s, a [Gd]inj of at least 38.3 mM is needed
to surpass the 75% threshold. Contrarily, for Qinj=4 ml/s
and Qblood=10 ml/s, a [Gd]inj of only 22.3 mM/s is
required.
Explicitly, for Qinj=2 ml/s, optimal [Gd]inj was found at
6.4 mM for Qblood=0 ml/s, at 38.3 mM for Qblood=10 ml/s,
at 70.1 mM for Qblood=20 ml/s, and finally at 102.0 mM
for Qblood=30 ml/s. For Qinj=4 ml/s, optimal [Gd]inj was
found at 6.4 mM for Qblood=0 ml/s, at 22.3 mM for
Qblood=10 ml/s, at 38.3 mM for Qblood=20 ml/s, and at
54.2 mM for Qblood 30 ml/s.
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For Qinj=2 ml/s, 102.0 mM is the lowest [Gd]inj
providing a SI above the 75% threshold for all four aortal
blood flow rates, whereas the lowest optimal [Gd]inj for
Qinj=4 ml/s is 54.2 mM. Both sets of optimal injection
parameters lead to an injected gadolinium dose of ap-
proximately 3.1 mmol.
For low-dose intra-arterial 3D MR aortography in pa-
tients, we chose the [Gd]inj with the higher injection rate,
[Gd]inj=54.2 mM and Qinj=4 ml/s, since higher injection
rates ensure better mixing of gadolinium with blood at
the tip of the catheter. However, for practical reasons,
we applied 50 mM of [Gd]inj, which corresponds to
1:10 of the stock solution of Gd-DTPA.
Patient study
In all patients, low-dose intra-arterial MR aortography was
feasible and well tolerated. No side effects occurred. In
general, high-spatial-resolution intra-arterial 3D CE-MR
aortography demonstrated a clear delineation of the ab-
dominal aorta and its major branching arteries. Disturbing
venous overlay or motion artifacts were not observed.
Mean CNR±SD was 70.2±15.2 for the infrarenal abdom-
inal aorta, 58.6±12.3 for the renal artery, and 67.4±12.3 for
the common iliac artery.
MIPs obtained with low-dose intra-arterial 3D CE-MR
aortography in patients are presented in the upper row of
Fig. 2a–e. For comparison, the corresponding DSA images
are illustrated in the lower row. Abdominal aorta, mesen-
teric, and parts of the iliac arteries are clearly visualized in
all MIPs.
The DSA image in Fig. 2a (lower row) acquired before
PTA and stenting demonstrates bilateral high-grade steno-
ses of the common iliac artery. The upper row of Fig. 2a
displays the corresponding MR aortogram after bilateral
stenting of the common iliac artery. Signal loss is observed
within the stent lumen because of shielding artifacts of
the metal meshwork [20]. AMIP-reconstructedMR aorto-
gram of a living kidney donor is shown in Fig. 2c (upper
row). Two renal arteries are depicted on the right side
and one single artery on the left side. The DSA image
in Fig. 2d (lower row) displays a short high-grade ste-
nosis of the right common iliac artery. Good signal en-
hancement of the iliac lumen is observed in intra-arterial
MR aortograms acquired after angioplasty. Similar find-
ings are demonstrated in Fig. 2b and e.
Discussion
Adequate signal enhancement of the aortal lumen will
be mandatory for MR-guided endovascular interven-
tions. Our study demonstrates that the theoretically de-
rived low-dose intra-arterial injection protocol is feasible
and may provide high-spatial-resolution 3D CE-MR aor-
tograms with high CNR of the aorta and its branching
arteries. The derived injection protocol accounts for the
aortal flow conditions (≤30 ml/s), the paramagnetic prop-
erties of gadolinium-based contrast agents (R1, R2
*), and
conventional T1-weighted spoiled gradient-echo sequences.
Optimal injection parameters were determined by simula-
tions based on a theoretical model, whose prediction value
has been validated in phantom and animals studies [9,10], as
well as in a recent patient study [8].
Due to the rapid dilution of gadolinium-based contrast
agents in circulating blood, repetitive injections during an
interventional procedure will be mandatory. However, the
total administered dose of gadolinium during an interven-
tion should not exceed the approved limits of the Food and
Drug Administration (FDA). The total amount of injected
Fig. 1 a Quantitative results obtained from the simulation with
Qinj=2 ml/s for four aortal blood flow rates: Qblood=0, 10, 20, and
30 ml/s. The horizontal line indicates 75% of the corresponding
maximum of SI. A vertical line indicates the simulated SI for
[Gd]inj=50 mM. b Quantitative results obtained from the simula-
tion with Qinj=4 ml/s for four aortal blood flow rates: Qblood=0, 10,
20, and 30 ml/s. The horizontal line indicates 75% of the cor-
responding maximum of SI. For [Gd]inj=54.2 mM, indicated by the
vertical line, the simulated signal intensities of all four aortal flow
rates lie above the 75% threshold
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gadolinium is based on the [Gd]inj, Qinj and the injection
length, which is 15 s. Therefore, the total injected gadolin-
ium dose amounted to 3 mmol, even if a diluted Gd-DTPA
solution of only 50 mM of gadolinium is administered.
Assuming an average body weight of 70 kg, a dose of
3 mmol gadolinium corresponds to approximately 14% of
the FDA-approved maximum dose. Thus, only seven intra-
aortal injections will be permissible for an adult patient of
average body weight until the FDA-approved maximum
dose is exceeded. However, a complex endovascular inter-
vention might require more than seven intra-aortal injec-
tions, which might limit the application of this technique.
According to the theoretical model, the SI for a specific
CE-MRA sequence is a function of the [Gd]blood. Since the
optimal [Gd]blood for a given blood flow rate is approxi-
mately proportional to the product of [Gd]inj and Qinj
(Eq. 4), different combination of [Gd]inj and Qinj can be
used to achieve identical arterial enhancement. Therefore,
a lower optimal [Gd]inj of 54.2 mM was found for Qinj=
4 ml/s in our study, whereas the lower Qinj of 2 ml/s
required a correspondingly higher [Gd]inj of 102.0 mM.
Since we have optimized the product of [Gd]inj and Qinj
regarding 75% of maximum signal enhancement in the
aorta, a further reduction of the gadolinium dose can be
achieved by a further reduction of injection length. In our
study, the k-space coverage was 75% (TA=20 s, injection
length=15 s). However, a further reduction down to 50%
coverage might be feasible without significant loss of
signal-to-noise ratio. This was recently demonstrated in
an aortal phantom study [16].
Additionally, a shorter acquisition time might also
enable a reduction of the injection length and injected
gadolinium dose. Parallel imaging techniques like Sensi-
tivity Encoding (SENSE) [21] or generalized autocalibrat-
ing partially parallel acquisition (GRAPPA) [22] permits to
speed up MR data acquisition by a factor of two or even
higher. A corresponding reduction of injection length and
thereby of gadolinium dose of at least 50% might be
possible. Nevertheless, further studies are obligatory to
evaluate the potential of these techniques to minimize the
injected gadolinium dose while preserving the SNR and
diagnostic quality of intra-arterial MR aortography.
Recently, first results of intra-arterial MR angiography in
patients have been reported [8, 23, 24]. However, these
studies have applied injection protocols, which were either
not aimed to minimize the injected gadolinium dose or not
optimized for the aortal flow condition. Paetzel et al. [23]
showed that intra-arterial MR aortography is feasible by
injecting a gadodiamide dose of 5 mmol ([Gd]inj=83 mM,
Qinj=3.5 ml/s, injection length 17 s). For an adult patient
Fig. 2 Upper row: MIP-reconstructed intra-arterial 3D CE-MR
aortograms, lower row: corresponding DSA images in a.-p. pro-
jection. a Fifty-nine-year-old male patient suffering from PAOD
with a high-grade stenosis of the left common iliac artery and a mid-
grade stenosis of the right common iliac artery. The left and right
side were treated with a 10- and 40-mm Smart stent (Cordis, Miami,
FL, USA), respectively. Due to shielding effects no signal enhance-
ment can be depicted in the lumen of the stent. However, the run-off
in the periphery is excellently visualized. b Sixty-seven-year-old
male patient suffering from PAOD with multiple atherosclerotic
plaques in the infrarenal aorta and the left common artery. c Sixty-
three-year-old male living renal kidney donor. The abdominal aorta,
inferior mesenteric artery, iliac arteries and some lumbar arteries are
clearly visualized. Two renal arteries exist on the right side, while
there is only a single renal artery on the left side. Homogenous
signal enhancement of the right kidney is observed. The left kidney
shows a perfusion deficit in the periphery (arrow). d Fifty-eight-
year-old male patient with a non-Hodgkin’s lymphoma suffering
from a high-grade stenosis of the common iliac artery on the right
side. The patient was treated with PTA. A plaque of the distal aorta
is nicely depicted in the DSA image and the intra-arterial MR
aortogram. e Fifty-six-year-old female patient with multiple athero-
sclerotic plaques who was treated with PTA of the common iliac
arteries on both sides
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with an average body weight of 70 kg, this protocol would
permit only four repetitive injections. The SNR values
obtained in their study were referenced to the SI in the
left psoas muscle. Therefore, they can not be compared
with our values, which were referenced to the standard
deviation of SI measured in a ROI outside the body.
Bilecen et al. proposed a low-dose intra-arterial injection
protocol for 3D CE-MRA of the infrainguinal arteries in
PAOD patients. Good image quality and high arterial
enhancement of the infrainguinal arteries were achieved
with [Gd]inj=50 mM, Qinj=1.0 ml/s and TA=20 s [8].
Although both protocols include the same [Gd]inj the
total injected gadolinium in their study amounted to only
1 mmol as the infrainguinal blood flow rate is small with
≤5 ml/s. In our study we used extra-cellular gadolinium
chelates, Magnevist, as contrast agent. Blood-pool agents
provide the opportunity to image during the steady state
of contrast agent concentration. The impact of intra-arterial
injection of blood-pool agent is not yet known, but might
be taken into account to reduce the total amount of in-
jected gadolinium during endovascular interventions [25].
In conclusion, the proposed low-dose injection protocol
for intra-arterial high-spatial-resolution 3D CE-MR aortog-
raphy in patients provided good luminal enhancement of
the aorta and its branching arteries. Simulations based on a
theoretical model were performed to determine the optimal
injection parameters under aortal blood flow conditions.
The injected gadolinium dose was 3 mmol permitting ap-
proximately seven injections in adult patients of average
body weight without exceeding the FDA-approved maxi-
mum gadolinium dose. This study is a first step towards
low-dose intra-arterial 3D MR aortography in humans.
Methodical and technical improvements are necessary to
further reduce the injected gadolinium dose in order to
enable a sufficient number of repetitive intra-aortal injec-
tions during an MR-guided endovascular intervention.
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Appendix
MR angiography with T1-shortening contrast agents typ-
ically employs spoiled gradient-echo sequences. The SI of
a spoiled gradient-echo sequence is given by
SI / sin   eTE=T2 1 e
TR=T1
1 eTR=T1cos ; (1)
where TR, TE, and α are the repetition time, echo time, and
flip angle, respectively. For CE-MRA, T1 and T2* refer to
the relaxation rates of the blood-contrast mixture (T1bc,
T2bc*), which depend on [Gd]blood via
1
T1bc
¼ 1
T1b
þ R1 Gd½ blood and
1
T2bc ¼
1
T2b þ R2  Gd½ blood;
(2)
with the relaxation rates of blood, T1b and T2b*, and the
relaxivities of gadolinium, R1=4.5 mM
−1s−1and R2*=6.0
mM−1s−1. Additionally, according to the dilution model
[9], [Gd]blood can be expressed as a function of [Gd]inj, Qinj,
and Qblood of the artery of interest
Gd½ blood ¼ Gd½ inj 
Qinj
Qinj þ Qblood
; (3)
For Qinj≤Qblood, Eq. (3) reduces to
Gd½ blood 
Gd½ inj  Qinj
Qblood
; (4)
Inserting T1bc and T2bc from Eq. (2) and [Gd]blood from
Eq. (4) in Eq. (1) provide the SI of a particular spoiled
gradient-echo sequence with [Gd]inj, Qblood, and Qinj.
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